Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$51.61 USD
-1.12 (-2.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $51.54 -0.07 (-0.14%) 5:22 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -38.99 | -24.07 | -30.91 | -24.64 | -30.77 |
Depreciation/Amortization & Depletion | 1.96 | 1.96 | 1.96 | 1.95 | 1.96 |
Net Change from Assets/Liabilities | 2.93 | -0.76 | -1.15 | 2.98 | 2.50 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 9.16 | 2.08 | 2.33 | -5.51 | 8.94 |
Net Cash From Operating Activities | -24.94 | -20.78 | -27.77 | -25.22 | -17.38 |
Property & Equipment | 0.00 | -0.01 | -0.02 | -0.01 | -0.02 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.50 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 |
Net Cash from Investing Activities | 0.00 | -0.01 | -0.02 | -0.01 | 0.53 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 180.02 | 15.15 | 0.00 | 53.74 | 14.48 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -1.06 | -0.13 | -0.02 | 0.00 |
Net Cash from Financing Activities | 180.02 | 14.09 | -0.13 | 53.72 | 14.48 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 155.08 | -6.70 | -27.92 | 28.49 | -2.37 |
Cash at Beginning of Period | 14.60 | 21.30 | 49.22 | 20.73 | 23.10 |
Cash at End of Period | 169.68 | 14.60 | 21.30 | 49.22 | 20.73 |
Diluted Net EPS | -2.36 | -2.87 | -5.85 | -5.85 | -13.49 |
Fiscal Year End for Soleno Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -43.25 | -21.40 | -38.99 | -27.69 | -16.83 |
Depreciation/Amortization & Depletion | 0.98 | 0.49 | 1.96 | 1.47 | 0.98 |
Net Change from Assets/Liabilities | -2.11 | 1.94 | 2.93 | 1.02 | 0.93 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 14.19 | 6.44 | 9.16 | 6.57 | 2.63 |
Net Cash From Operating Activities | -30.18 | -12.53 | -24.94 | -18.63 | -12.29 |
Property & Equipment | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -236.15 | -115.23 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -236.17 | -115.24 | 0.00 | 0.00 | 0.00 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 153.69 | 0.94 | 180.02 | 56.46 | 17.06 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 153.69 | 0.94 | 180.02 | 56.46 | 17.06 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -112.66 | -126.83 | 155.08 | 37.84 | 4.77 |
Cash at Beginning of Period | 169.68 | 169.68 | 14.60 | 14.60 | 14.60 |
Cash at End of Period | 57.02 | 42.85 | 169.68 | 52.44 | 19.37 |
Diluted Net EPS | -0.57 | -0.59 | 0.28 | -0.95 | -0.81 |